The Latest Cardiac and Vascular News
Financing led by Andera Partners including Cormorant Asset Management, Taglich Brothers Inc., Squarepoint Capital, and Richmond Brothers to Support Premarket Approval of Revivent TC® System for Patients with Ischemic Heart Failure MANSFIELD, Mass., April 13, 2023 /PRNewswire/ — BioVentrix, Inc., a privately held medical device company developing minimally invasive therapies to directly treat the dilated left […]
SAN RAMON, Calif.–(BUSINESS WIRE)–BioVentrix, Inc., a privately held medical device company focused on treating congestive heart failure (CHF) via Transcatheter based Ventricular Restoration (TCVR), today announced that the German Institute for Hospital Remuneration (InEK) has renewed the NUB Status 1 reimbursement designation in Germany for the Revivent TC™ TransCatheter Ventricular Enhancement […]
SAN RAMON, Calif.–(BUSINESS WIRE)–BioVentrix, Inc., developer of the first hybrid transcatheter device for left ventricular remodeling after a heart attack, today announced that the Company has resumed cases in the pivotal ALIVE Trial studying Less Invasive Ventricular Enhancement, or LIVE™ Therapy, using the Revivent TC™ Transcatheter Ventricular Enhancement System. The […]
Study Published in European Journal of Heart Failure Shows Significant and Sustained Improvement in Heart Function, Symptom Relief and Quality of Life Using Less Invasive Left Ventricular Enhancement Device SAN RAMON, Calif.–(BUSINESS WIRE)–BioVentrix, Inc., developer of the first less invasive system for left ventricular remodeling, today announced online publication of positive […]
To demonstrate that treatment with the Revivent TC™ System is more effective than Guideline Directed Medical Therapy (GDMT) for the treatment of ischemic heart failure SAN RAMON, Calif., Sept. 23, 2019 /PRNewswire/ — The Revivent TC™ System has continued to deliver impressive results when evaluating post-market data in Europe. The last 35 consecutive cases […]
